The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
Open accessAbstract
Significance: Nanoparticle-based therapeutics rely on the enhanced permeability and retention effect to localize in solid tumors and not healthy tissue. These phenomena are rationalized from animal models of human disease. Since these models poorly represent human tumors, there is a need to obtain information from humans to better understand how nanoparticle-based therapeutics perform in humans. Here, we collected tumor and nonneoplastic tissue biopsies from cancer patients who have been administered CRLX101 and show that the intact nanoparticles localize in human tumors and not in adjacent tissues. Sufficient concentrations reach the tumors to cause down-regulation of topoisomerase I and carbonic anhydrase IX. These results will aid in better understanding how nanoparticle therapeutics function in humans and how to better design future therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“N experimental therapeutics are being used to deliver a variety of different drug molecules to patients with solid tumors (1).”
BackgroundSelf-citationMaeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179 · cited 1×
“Human tumors also express a high degree of heterogeneity (10, 11).”
BackgroundBiological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Contrast agents for molecular photoacoustic imaging
Weber, J., Beard, P. C., & Bohndiek, S. E. (2016) · Nature Methods · doi:10.1038/nmeth.3929 · Cited by 1,270
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
Metadata
- Authors
- Clark, A. J., Wiley, D. T., Zuckerman, J. E., Webster, P., Chao, J., Lin, J., Yen, Y., & Davis, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-03-21
- Volume
- 113
- Issue
- 14
- Pages
- 3850-3854
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2306899626
- Cited by
- 168
- References
- 3
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.